In a decision that surprised many, the U.S. Food and Drug Administration (FDA) last week denied approval of Biomarin’s FVIII gene therapy, branded Roctavian. The...
Three decades of people with hemophilia unexposed to contaminated factor products and current treatments capable of suppressing and eliminating HIV and HCV, respectively, has again...
Hemlibra (emicizumab) is indicated in Canada for hemophilia A patients with or without factor VIII inhibitors as routine prophylaxis to prevent bleeding or reduce the...
The Plasma Protein Therapeutics Association (PPTA) represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the...
The Hemophilia Research Grants Review Committee, under the chairmanship of Dr. Manuel Carcao, met earlier this year and announced the 2020 grant recipients for the...
